PMID: 7032817Dec 1, 1981Paper

Effect of angiotensin II and converting enzyme inhibitor (captopril) on blood pressure, plasma renin activity and aldosterone in primary aldosteronism

Clinical Science
F ManteroC Scaroni

Abstract

1. Patients with idiopathic hyperaldosteronism (IHA) show a response of aldosterone to posture which is not present in patients with aldosterone-producing adenoma (APA). We have determined whether this could be explained by a different sensitivity to angiotensin II. 2. Angiotensin II was infused in gradually increasing doses in six patients with APA and in seven patients with IHA. No changes in aldosterone concentration were found at the end of each period in APA, whereas there was a significant increase in IHA; blood pressure rose by a similar extent in both groups. 3. In order to evaluate the role of endogenous angiotensin II, captopril, a converting enzyme inhibitor, was administered to six patients with APA and five patients with IHA at a dose of 75 mg/day for 1 week. There was a significant fall of mean blood pressure in IHA and only minimal changes in APA. Plasma renin activity and plasma in urinary aldosterone were unchanged in APA. In IHA there was a small increase in upright plasma renin activity and a slight decrease in both plasma and urinary aldosterone, but these changes were not significant. 4. These findings further support the idea that idiopathic hyperaldosteronism is a clinical state different from that occurr...Continue Reading

Citations

Jan 1, 1987·Clinical and Experimental Hypertension. Part A, Theory and Practice·H MurataniM Fujishima
Sep 20, 2011·European Journal of Internal Medicine·Norlela Sukor
Dec 1, 2010·Best Practice & Research. Clinical Endocrinology & Metabolism·Marcus Quinkler, Paul M Stewart
Oct 1, 1984·The American Journal of Medicine·R K FergusonH H Rotmensch
Apr 21, 1999·Clinical Endocrinology·G P RossiA C Pessina
Mar 12, 2005·Arquivos brasileiros de endocrinologia e metabologia·Franco Mantero, Nora Albiger
Jan 29, 2011·Journal of the Renin-angiotensin-aldosterone System : JRAAS·Christina WesterdahlStig Valdemarsson
Jul 11, 2006·Der Internist·M Quinkler, M Reincke
May 1, 1992·Clinical Endocrinology·C HamblingW A Bartlett
Jun 17, 2008·The Journal of Clinical Endocrinology and Metabolism·John W FunderUNKNOWN Endocrine Society
Nov 13, 2008·The Journal of Clinical Endocrinology and Metabolism·Guillermo E UmpierrezLawrence S Phillips
Mar 24, 2006·Expert Opinion on Pharmacotherapy·Salim Janmohamed, Pierre-Marc G Bouloux
Nov 2, 2011·Endocrine·Norlela Sukor
Jul 1, 1985·Hypertension·R L WeinsierT B Van Itallie
Jun 27, 2012·Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine·Akiyo Tanabe, Atsuhiro Ichihara
Apr 6, 2001·Journal of Hypertension·P O LimT M MacDonald
Mar 5, 2016·The Journal of Clinical Endocrinology and Metabolism·John W FunderWilliam F Young
Nov 1, 2007·Expert Review of Endocrinology & Metabolism·Paola SartoratoFranco Mantero
Feb 10, 2011·Reviews in Endocrine & Metabolic Disorders·Asterios Karagiannis
Apr 3, 2021·Frontiers in Endocrinology·Jung Soo LimAdina F Turcu
Feb 18, 2018·Endocrine Regulations·Frederick-Anthony FarrugiaNikolaos Koliakos
Apr 1, 1993·The Journal of Steroid Biochemistry and Molecular Biology·G OpocherF Mantero

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Diseases: Risk Factors

Cardiovascular disease is a significant health concern. Risk factors include hypertension, obesity, dyslipidemia and smoking. Women who are postmenopausal are at an increased risk of heart disease. Here is the latest research for risk factors of cardiovascular disease.